| Drug Type Fusion protein | 
| Synonyms PDL1-IL15 Affimer® fusion proteins, AVA 32, AVA32 | 
| Target | 
| Action modulators, inhibitors | 
| Mechanism IL-2R modulators(Interleukin-2 receptor modulators), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 01 Dec 2023 | 






